Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Hikma Pharmaceuticals Plc Stock Quote

Hikma Pharmaceuticals Plc (LSE: HIK)

GBX 1,789.00
(0.8%)
GBX 15.00
Price as of April 18, 2024, 11:30 a.m. ET

Hikma Pharmaceuticals Plc Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
HIK -1.33% +7.03% +1.37% +727%
S&P +20.88% +72.88% +11.56% +313%

Hikma Pharmaceuticals Plc Company Info

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.